Clinical trial · Interventional
Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a multicenter study. It plans to screen 200 patients with pulmonary nodule lesions with ground glass as the main body, take CT thin-layer scanning 3D reconstruction, apply AI and fragment omics technology to evaluate the risk of malignant transformation of pulmonary nodules, and use microwave ablation to treat pulmonary nodules and combine intraoperative rapid pathology technology to determine the nature of puncture tissue and the degree of ablation, and then explore the optimal ablation time and ablation power.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Microwave ablation combined with biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Microwave ablation combined with biopsy
- description
- Microwave ablation combined with biopsy
- interventionNames
- Procedure: Microwave ablation combined with biopsy
Primary outcomes (3)
- measure
- Local contral rate
- timeFrame
- up to 36 months
- description
- LCR is the rate of CR, PR plus SD
- measure
- Recurrence-free survival
- timeFrame
- up to 36 months
- description
- It estimates the recurrence-free rate of patients who have already survived, with no history of metastasis, a certain period of time.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≤ 75 years; 2. GGN patients with the maximum axial diameter of the lesion in the lung window ≤ 3 cm; 3. Refusing radical surgery or being unable to tolerate surgical treatment; 4. Normal coagulation function, platelet count ≥ 60 × 109 /L; 5. ECOG score ≤ 2 points; Exclusion Criteria: 1. Patients with the maximum axial diameter of the lesion in the lung window greater than 3 cm 2. Platelets \<50×109 /L 3. Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term 4. Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis and pulmonary hypertension 5. Patients whose anticoagulant therapy or antiplatelet drugs have been discontinued for less than 5 days before ablation 6. Patients with severe heart, liver, kidney and brain dysfunction 7. Patients with severe anemia, dehydration and cachexia that cannot be corrected or improved in the short term 8. Patients with an estimated survival period of less than 6 months
References
Publications (0)
Data not yet available